高级检索
    孙林林, 陈葶, 白运焕, 吴岭, 陈茂杰. 血清高迁移率族蛋白B1与可溶性髓系细胞触发受体1联合检测对脓毒症并发急性肾损伤的诊断价值[J]. 临床肾脏病杂志, 2024, 24(3): 195-199. DOI: 10.3969/j.issn.1671-2390.2024.03.003
    引用本文: 孙林林, 陈葶, 白运焕, 吴岭, 陈茂杰. 血清高迁移率族蛋白B1与可溶性髓系细胞触发受体1联合检测对脓毒症并发急性肾损伤的诊断价值[J]. 临床肾脏病杂志, 2024, 24(3): 195-199. DOI: 10.3969/j.issn.1671-2390.2024.03.003
    Sun Lin-lin, Chen Ting, Bai Yun-huan, Wu Ling, Chen Mao-jie. Diagnostic value of combined detection of serum levels of HMGB1 and sTREM-1 in sepsis complicated with acute kidney injury[J]. Journal of Clinical Nephrology, 2024, 24(3): 195-199. DOI: 10.3969/j.issn.1671-2390.2024.03.003
    Citation: Sun Lin-lin, Chen Ting, Bai Yun-huan, Wu Ling, Chen Mao-jie. Diagnostic value of combined detection of serum levels of HMGB1 and sTREM-1 in sepsis complicated with acute kidney injury[J]. Journal of Clinical Nephrology, 2024, 24(3): 195-199. DOI: 10.3969/j.issn.1671-2390.2024.03.003

    血清高迁移率族蛋白B1与可溶性髓系细胞触发受体1联合检测对脓毒症并发急性肾损伤的诊断价值

    Diagnostic value of combined detection of serum levels of HMGB1 and sTREM-1 in sepsis complicated with acute kidney injury

    • 摘要:
      目的  探讨血清高迁移率族蛋白B1(high mobility group protein B1,HMGB1)、可溶性髓系细胞触发受体1(soluble myeloid cell trigger receptor-1,sTREM-1)联合检测对脓毒症并发急性肾损伤(acute kidney injury,AKI)的诊断价值。
      方法  回顾性选择徐州市中心医院2020年1月1日至2022年1月31日收治的156例脓毒症患者,另选取同期68例体检健康者为对照组。对比两组受试者血清HMGB1、sTREM-1水平,多因素Logistic回归分析脓毒症并发AKI的影响因素,受试者工作特征曲线分析血清HMGB1、sTREM-1水平对脓毒症并发AKI的诊断价值。
      结果  脓毒症组患者血清HMGB1172 530(133 870,204 010)ng/L比83 720(63 480,99 870)ng/L、sTREM-1(49.56 ± 8.03)ng/L比(24.96 ± 5.24)ng/L水平明显高于对照组(P<0.05);多因素Logistic分析显示,血肌酐(OR = 1.079,95%CI:1.037~1.122)、HMGB1(OR = 1.933,95%CI:1.376~2.714)、sTREM-1(OR = 1.201,95%CI:1.101~1.309)为脓毒症并发AKI的独立危险因素(P<0.05);受试者工作特征曲线显示,HMGB1联合sTREM-1曲线下面积(area under the curve,AUC) = 0.928,95%CI:0.876~0.963诊断脓毒症并发AKI的敏感度、特异度、准确度高于HMGB1(AUC = 0.790,95%CI:0.718~0.851)、sTREM-1(AUC = 0.778,95%CI:0.705~0.840)诊断。
      结论  脓毒症患者血清HMGB1、sTREM-1水平明显增高,是脓毒症并发AKI的独立危险因素。

       

      Abstract:
      Objective  To explore the diagnostic value of combined detection of serum high mobility group protein B1 (HMGB1) and soluble myeloid cell trigger receptor-1 (sTREM-1) in sepsis complicated with acute kidney injury (AKI).
      Methods From January 1, 2020 to January 31, 2022, 156 hospitalized septic patients were retrospectively selected and 68 healthy subjects in the same period were selected as control group. The serum levels of HMGB1 and sTREM-1 were compared between two groups. And the influencing factors of sepsis complicated with AKI were examined by multivariate Logistic regression. The diagnostic value of serum level of HMGB1/sTREM-1 for sepsis complicated with AKI was explored by receiver characteristic curve.
      Results  The serum levels of HMGB1 172 530(133 870, 204 010) to 83 720(63 480, 99 870) ng/L and sTREM-1(49.56 ± 8.03)ng/L vs(24.96 ± 5.24)ng/L were significantly higher in sepsis group than those in control group (P<0.05). Multivariate Logistic analysis revealed that serum creatinine(OR = 1.079, 95%CI:1.037-1.122), HMGB1 (OR = 1.933, 95%CI:1.376-2.714) and sTREM-1 (OR = 1.201, 95%CI:1.101-1.309) were independent risk factors for sepsis complicated with AKI (P<0.05). The working characteristic curve indicated that HMGB1 plus sTREM-1 area under the curve (AUC) = 0.928, 95%CI:0.876-0.963 offered a higher sensitivity, specificity and accuracy in diagnosing sepsis complicated with AKI than HMGB1 (AUC = 0.790, 95%CI:0.718-0.851) and sTREM-1 (AUC = 0.778, 95%CI:0.705-0.840).
      Conclusion  The serum levels of HMGB1 and sTREM-1 are significantly up-regulated in septic patients. Both are independent risk factors for sepsis complicated with AKI.

       

    /

    返回文章
    返回